PDE3A
PDE3A (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.
Overview
Cyclic nucleotide phosphodiesterase with specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Also has activity toward cUMP. Independently of its catalytic activity it is part of an E2/17beta-estradiol-induced pro-apoptotic signalling pathway.
Open Targets scores its association with cancer at 0.70 (direct and indirect evidence; datatypes literature 0.91, genetic association 0.53, somatic mutation 0.23, clinical 0.96).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PDE3A (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.
- 1 · What it is
PDE3A (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.
- 2 · What goes wrong in cancer
Cyclic nucleotide phosphodiesterase with specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Also has activity toward cUMP.
- 3 · How drugs use it
No product in this corpus aims at PDE3A yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:8778 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q14432 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000172572 (association with cancer (MONDO_0004992) 0.70; per-cancer scores at or above 0.5: myeloproliferative neoplasm 0.59, essential thrombocythemia 0.58 (GraphQL API, CC0))
Biology
Cyclic nucleotide phosphodiesterase with specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Also has activity toward cUMP. Independently of its catalytic activity it is part of an E2/17beta-estradiol-induced pro-apoptotic signalling pathway. E2 stabilises the PDE3A/SLFN12 complex in the cytosol, promoting the dephosphorylation of SLFN12 and activating its pro-apoptotic ribosomal RNA/rRNA ribonuclease activity. This apoptotic pathway might be relevant in tissues with high concentration of E2 and be for instance involved in placenta remodeling. Location: Membrane; Cytoplasm, cytosol (UniProt). Locus 12p12.2 (HGNC).
- Myeloproliferative neoplasms: Open Targets association 0.59 with myeloproliferative neoplasm (MONDO_0020076)
- Essential thrombocythaemia: Open Targets association 0.58 with essential thrombocythemia (MONDO_0005029)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.96. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PDE3A" OR ABSTRACT:"PDE3A" OR TITLE:"phosphodiesterase 3A" OR ABSTRACT:"phosphodiesterase 3A" OR TITLE:"cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A" OR ABSTRACT:"cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A" OR TITLE:"CGI-PDE" OR ABSTRACT:"CGI-PDE") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PDE3A, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPDE3B
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
- TargetCALR
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
- TargetRPS29
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
- TermErythromelalgia
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- TargetRTEL1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
- TargetSBDS
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
- TargetETNK1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
- TrialExtension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis).